PubMed Health⌕ Search

Biomedical subjects

D L Lindquist

Publications and source records attributed to D L Lindquist.

3 recordsLinked to original sources

Evaluation of bone marrow megakaryocyte ploidy distributions in persons with normal and abnormal platelet counts.

Using bone marrow smears of the type prepared routinely in clinical practice, we determined megakaryocyte ploidy distributions in five normal persons, eight patients with both normal platelet counts and normal bone marrow morphology, and 18 patients with quantitative platelet disorders. To include 2N and 4N megakaryocytes in the ploidy distribution histograms, all megakaryocytes were identified by serial immunologic labelling with rabbit antiserum to human platelet glycoproteins and rhodamine-conjugated goat anti-rabbit igG. Cell nuclei were concurrently Feulgen stained with bis-aminophenyl-oxdiazole, and the nuclear fluorescent signals were quantified photometrically. A modal megakaryocyte ploidy value of 32N was seen in 10 of the 13 persons with normal platelet counts, and geometric mean megakaryocyte ploidy values averaged 24.9N +/- 7.0N (arithmetic mean +/- SD). In these normal control individuals, 2N and 4N megakaryocytes accounted for 11.1% of all megakaryocytes, and 2.6% of the megakaryocytes were 128N. Shifts to a higher mean ploidy were observed in five of seven patients with idiopathic thrombocytopenic purpura, resulting from increased percentages of 64N and 128N megakaryocytes at the expense of 4N, 8N, and 16N cells. Shifts to lower ploidy were demonstrated in two patients with acute myelogenous leukemia and one patient each with thrombotic thrombocytopenic purpura and isoimmune thrombocytopenia. Four of five patients with essential thrombocythemia had strikingly abnormal megakaryocyte ploidy histograms characterized by the presence of unusually high ploidy 256N and 512N megakaryocytes. These 256N and 512N cells were virtually unique to the patients with essential thrombocythemia.(ABSTRACT TRUNCATED AT 250 WORDS)

Bone Marrow↗

Charcoal-dextran treatment of fetal bovine serum removes an inhibitor of human CFU-megakaryocytes.

Serum has been shown to have an inhibitory effect on the growth of human megakaryocyte colony-forming units (CFU-Meg), both in the methylcellulose and plasma clot systems. Charcoal-dextran (CD) treatment of fetal bovine serum (FBS), a method that is known to adsorb free hormones and various other substances from their protein-bound counterparts, has been used for the improvement of human erythroid colony growth. We now report a CD treatment of FBS to improve human CFU-Meg growth, using a modified plasma clot colony assay. We found 22.9 +/- 1.9 (SEM) colonies in cultures containing CD-treated FBS, as compared to 7.1 +/- 0.9 colonies with control FBS (different at p less than or equal to 0.0001). Serum treated with dextran alone produced 5.0 +/- 1.6 colonies, which did not differ from control FBS. Cultures containing CD-treated human AB serum, human AB plasma, and citrated bovine plasma yielded significantly (p less than 0.05) fewer colonies than those with CD-treated FBS. Endotoxin, cortisol, T3, T4, insulin, estradiol, testosterone, and erythropoietin levels were not changed in a consistent direction by the CD treatment. Our treatment of FBS with CD allows improved growth of human CFU-Meg colonies and likely represents the removal of an as-yet-undefined inhibitor(s) of CFU-Meg. This technique provides the ability to assay for stimulators or potentiators less hampered by the influence of an undefined inhibitor(s).

Animals↗